Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Q Huang, Y Le, S Li, Y Bian - Respiratory Research, 2024 - Springer
Acute respiratory distress syndrome (ARDS) is a common condition associated with critically
ill patients, characterized by bilateral chest radiographical opacities with refractory …

Umbilical cord blood and cord tissue banking as somatic stem cell resources to support medical cell modalities

T Nagamura-Inoue, F Nagamura - Inflammation and Regeneration, 2023 - Springer
Human umbilical cord blood (CB) and umbilical cord tissue (UC) are attractive sources of
somatic stem cells for gene and cell therapies. CB and UC can be obtained noninvasively …

Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now?

GF Curley, CM O'Kane, DF McAuley… - American Journal of …, 2024 - atsjournals.org
There is considerable interest in the potential for cell-based therapies, particularly
mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory …

Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double …

C Pochon, C Laroye, A Kimmoun, L Reppel… - Frontiers in …, 2023 - frontiersin.org
Background The COVID-19 pandemic caused a wave of acute respiratory distress syndrome
(ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical …

Vascular leak in sepsis: physiological basis and potential therapeutic advances

RR McMullan, DF McAuley, CM O'Kane, JA Silversides - Critical Care, 2024 - Springer
Sepsis is a life-threatening condition characterised by endothelial barrier dysfunction and
impairment of normal microcirculatory function, resulting in a state of hypoperfusion and …

Investigational pharmacological agents for the treatment of ARDS

K Aribindi, M Lim, S Lakshminrusimha… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous
form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that …

Mesenchymal stromal cells in acute respiratory distress syndrome: more questions than answers

JE Millar, CM O'Kane - American Journal of Respiratory and Critical …, 2023 - atsjournals.org
An effective treatment for acute respiratory distress syndrome (ARDS) remains elusive.
Preclinical studies have demonstrated therapeutic potential of multiple mesenchymal …

An update on the pharmacological management of acute respiratory distress syndrome

D Battaglini, IG Iavarone… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Acute respiratory distress syndrome (ARDS) is characterized by acute
inflammatory injury to the lungs, alterations in vascular permeability, loss of aerated tissue …

Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

J Qin, G Wang, D Han - Stem Cell Reviews and Reports, 2024 - Springer
Abstract Background The Coronavirus disease-2019 (COVID-19) pandemic continues, and
the death toll continues to surge. This meta-analysis aimed to determine the efficacy of …

[HTML][HTML] Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

XY Hou, LM Danzeng, YL Wu, QH Ma… - World Journal of Stem …, 2024 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID-19) is an acute respiratory infection caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection …